Literature DB >> 15024582

Histone deacetylase inhibitor, FK228, induces apoptosis and suppresses cell proliferation of human glioblastoma cells in vitro and in vivo.

Hiroki Sawa1, Hiromi Murakami, Masaoki Kumagai, Matsuyoshi Nakasato, Shigeru Yamauchi, Nozomu Matsuyama, Yasuo Tamura, Akira Satone, Wataru Ide, Ikuo Hashimoto, Hajime Kamada.   

Abstract

We investigated the effects of FK228 on cell proliferation and apoptosis against human glioblastoma (GM) T98G, U251MG, and U87MG cells. Upon exposure to FK228, cell proliferation was inhibited, and apoptosis detected by the cleavage of CPP32 was induced. FK228 increased the expression levels of p21 (WAF-1) and of pro-apoptotic Bad protein in all GM cells. Furthermore, FK228 treatment also reduced the anti-apoptotic protein Bcl-xL in all GM cells and anti-apoptotic Bcl-2 in U87MG cells, thereby shifting the cellular equilibrium from life to death. An increased accumulation of histone H4 was detected in the p21 (WAF-1) promoter and the structural gene (exon 2) and the Bad structural gene (exon 2 and 3) upon treatment with FK228, as assessed by chromatin immunoprecipitation (ChIP) assay. Thus, the results indicated that an increased expression of p21 (WAF1) and Bad due to FK228 is regulated, at least in part, by the degree of acetylation of the gene-associated histone. We also found that FK228 inhibits cellular invasiveness and decreases MMP-2 activity. In addition, the growth of transplanted human GM m-3 cells into the subcutaneous tissue of hereditary athymic mice was significantly inhibited, and apoptosis was induced with FK228 treatment. The results suggested that FK228 might be useful in the treatment of human GM, although further studies will be needed.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15024582     DOI: 10.1007/s00401-004-0841-3

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  21 in total

Review 1.  Novel delivery strategies for glioblastoma.

Authors:  Jiangbing Zhou; Kofi-Buaku Atsina; Benjamin T Himes; Garth W Strohbehn; W Mark Saltzman
Journal:  Cancer J       Date:  2012 Jan-Feb       Impact factor: 3.360

2.  Phase I study of panobinostat in combination with bevacizumab for recurrent high-grade glioma.

Authors:  J Drappatz; E Q Lee; S Hammond; S A Grimm; A D Norden; R Beroukhim; M Gerard; D Schiff; A S Chi; T T Batchelor; L M Doherty; A S Ciampa; D C Lafrankie; S Ruland; S M Snodgrass; J J Raizer; P Y Wen
Journal:  J Neurooncol       Date:  2011-10-08       Impact factor: 4.130

3.  A phase I/II trial of the histone deacetylase inhibitor romidepsin for adults with recurrent malignant glioma: North American Brain Tumor Consortium Study 03-03.

Authors:  Fabio M Iwamoto; Kathleen R Lamborn; John G Kuhn; Patrick Y Wen; W K Alfred Yung; Mark R Gilbert; Susan M Chang; Frank S Lieberman; Michael D Prados; Howard A Fine
Journal:  Neuro Oncol       Date:  2011-03-03       Impact factor: 12.300

4.  Insulin-like growth factor 1/insulin-like growth factor 1 receptor signaling protects against cell apoptosis through the PI3K/AKT pathway in glioblastoma cells.

Authors:  Mingshi Zhang; Jinrui Liu; Mingjun Li; Shihua Zhang; Yanmei Lu; Yanqiu Liang; Kai Zhao; Yingfu Li
Journal:  Exp Ther Med       Date:  2018-06-21       Impact factor: 2.447

Review 5.  Epigenetic modification in chromatin machinery and its deregulation in pediatric brain tumors: Insight into epigenetic therapies.

Authors:  Eleonore Maury; Rintaro Hashizume
Journal:  Epigenetics       Date:  2017-01-06       Impact factor: 4.528

Review 6.  Epigenetics of neurological cancers.

Authors:  Shaun D Fouse; Joseph F Costello
Journal:  Future Oncol       Date:  2009-12       Impact factor: 3.404

Review 7.  Targeting of histone deacetylases in brain tumors.

Authors:  Jonas Ecker; Olaf Witt; Till Milde
Journal:  CNS Oncol       Date:  2013-07

Review 8.  Epigenetic changes in gliomas.

Authors:  Rebecca Burgess; Robert Jenkins; Zhiguo Zhang
Journal:  Cancer Biol Ther       Date:  2008-09-18       Impact factor: 4.742

9.  Causal Mechanistic Regulatory Network for Glioblastoma Deciphered Using Systems Genetics Network Analysis.

Authors:  Christopher L Plaisier; Sofie O'Brien; Brady Bernard; Sheila Reynolds; Zac Simon; Chad M Toledo; Yu Ding; David J Reiss; Patrick J Paddison; Nitin S Baliga
Journal:  Cell Syst       Date:  2016-07-14       Impact factor: 10.304

Review 10.  Deregulated chromatin remodeling in the pathobiology of brain tumors.

Authors:  Anastasia Spyropoulou; Christina Piperi; Christos Adamopoulos; Athanasios G Papavassiliou
Journal:  Neuromolecular Med       Date:  2013-03       Impact factor: 3.843

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.